Immunohistochemical evaluation of Ki-67, Cyclin D1 and β-catenin expression in the subtypes of triple negative breast cancer

Cover Page


Aim. To evaluate the expression levels of Ki-67 and cyclin D1 and β-catenin in the subtypes of triple negative breast cancer.

Methods. The study was conducted on the surgical material from 60 patients of clinical stage 2A (T1N1M0 or T2N0M0) who were treated at the Rostov Research Institute of Oncology from 2012 to 2015. For immunohistochemistry, antibodies to estrogen and progesterone receptors, cytokeratins 5/6, Ki-67, cyclin D1, β-catenin, HER2/neu and EGFR proteins were used.

Results. Triple negative breast cancer with the signs of basal epithelium was found to have a significantly higher expression level of Ki-67 compared to non-basal-like one. In some part of triple negative breast cancer samples overexpression of cyclin D1 was observed. The high level of cyclin D1 in the basal-like subtype was less common than in the subtypes without the signs of basal epithelium, but its average value was significantly higher. In triple negative cancer with cyclin D1 overexpression, the loss of β-catenin on the cell membrane and its abnormal accumulation in the cytoplasm was significantly more frequent. β-catenin translocation into the cell nucleus was observed only in basal-like triple negative cancer, and 2 times more often in case of cyclin D1 overexpression.

Conclusion. In triple negative breast cancer tumors with overexpression of cyclin D1 and abnormal expression of β-catenin are observed in some cases; these biomarkers can be considered as potential therapeutic targets for this group of tumors.

L N Vashchenko

Rostov Research Institute of Oncology

Author for correspondence.
Rostov-on-Don, Russia

T N Gudtskova

Rostov Research Institute of Oncology

Rostov-on-Don, Russia

E M Nepomnyashchaya

Rostov Research Institute of Oncology

Rostov-on-Don, Russia

N S Karnaukhov

Rostov Research Institute of Oncology

Rostov-on-Don, Russia

M V Kvarchiya

Rostov Research Institute of Oncology

Rostov-on-Don, Russia

  1. Zhukova L.G. Breast cancer with triple-negative phenotype in the Russian population of patients. Clinicalmorphological features. Voprosy onkologii. 2015; 61 (2): 189–194. (In Russ.)
  2. Brilliant Yu.M., Brilliant A.A., Sazonov S.V. Epithelial cadherins and associated molecules in invasive lobular breast cancer. Arkhiv patologii. 2017; 79 (1): 12–18. (In Russ.)
  3. Kit O.I., Shatova Yu.S., Frantsiyants E.M. et al. The path to personalized treatment of breast cancer patients. Voprosy onkologii. 2017; 63 (5): 719–723. (In Russ.)
  4. Шатова Ю.С., Франциянц Е.М., Новикова И.А. и др. Антиандрогенная терапия: новое направление таргетной терапии рака молочной железы. Соврем. ­пробл. науки и образования. 2017; 3. (дата обращения: 07.03.2018). [Shatova Yu.S., Frantsiyants E.M., Novikova I.A. et al. Antiandrogen therapy: a new direction in targeted therapy for breast cancer. Sovremennye problemy nauki i obrazovaniya. 2017; 3.
  5. (access date: 07.03.2018). (In Russ.)]
  6. Yanjiao He, Zhaoxia Liu, Chao Qiao et al. Expression and significance of Wnt signaling components and their target genes in breast carcinoma. Molecular Med. Reports. Published online on: 2013: 137–143. doi: 10.3892/mmr.2013.1774.
  7. Skvortsov V.A., Manikhas G.M. Cyclin D1 and its prognostic value in planning of endocrine therapy of women of postmenopousal age with breast cancer. Vrach-aspirant. 2012; 50 (1.3): 401–407. (In Russ.)
  8. Zhuo W., Zhang L., Wang Y. et al. Cyclin D1 G870A polymorphism is a risk factor for esophageal cancer among Asians. Cancer Invest. 2012; 30 (9): 630–636. doi: 10.3109/07357907.2012.726385.
  9. Gayatri R., Anuradha A. Cyclin D1 expression in ductal carcinoma of the breast and its correlation with ­other prognostic parameters. J. Can. Res. Therap. 2014; 10 (3): 671–675. doi: 10.4103/0973-1482.138135.
  10. Pestell R.G. New roles of Cyclin D1. Am. J. Pathol. 2013; 183 (1): 3–9. doi: 10.1016/j.ajpath.2013.03.001.
  11. Mohammadizadeh F., Hani M., Ranaee M., Baghe­ri M. Role of cyclin D1 in breast carcinoma. J. Res. Med. Sci. 2013; 18 (12): 1021–1025. PMID: 24523791.
  12. Tatarskiy V.V. The Wnt signaling pathway: prospects for pharmacological regulation. Uspehi molekularnoj onkologii. 2016; 3 (1): 28–31. (In Russ.)
  13. Prosperi J.R., Goss K.H. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. J. Curr. Drug. Targets. 2010; 11: 1074–1088. doi: 10.2174/138945010792006780.
  14. Xu J., Prosperi J.R., Choudhury N. et al. β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS One. 2015; 10 (2): e0117097. doi: 10.1371/journal.pone.0117097.
  15. Artamonova E.V. Palbociclib in combination with hormone therapy for luminal HER2-negative metastatic breast cancer: new highly effective strategy of drug treatment. Opukholi zhenskoy reproduktivnoy sistemy. 2017; 13 (3): 28–40. (In Russ.)


Abstract - 139

PDF (Russian) - 163


© 2019 Vashchenko L.N., Gudtskova T.N., Nepomnyashchaya E.M., Karnaukhov N.S., Kvarchiya M.V.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Свидетельство о регистрации СМИ ЭЛ № ФС 77-75008 от 1 февраля 2019 года выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор)